Abstract: A medical inhalation device or a component thereof having a diamond-like glass coating comprising hydrogen and on a hydrogen free basis about 20 to about 40 atomic percent of silicon, greater than 39 atomic percent of carbon, and less than 33 down to and including zero atomic percent of oxygen.

Abstract: A composition for modifying a surface of a substrate, the composition comprising: (a) a first polyfluoropolyether silane of the Formula Ia: CF3CF2CF2O(CF(CF3)CF2O)pCF(CF3)—C(O)NH(CH2)3Si(Y)3 wherein each Y is independently a hydrolyzable group and wherein p is 3 to 50; and (b) a second polyfluoropolyether silane of the Formula IIa: (Y?)3Si(CH2)3NHC(O)—CF2O(CF2O)m(C2F4O)qCF2-C(O)NH(CH2)3Si(Y?)3 wherein each Y? is independently a hydrolyzable group and wherein m is 1 to 50 and q is 3 to 40. A method of making a medicinal inhalation device or a component of a medicinal inhalation device comprising a step of applying to at least a portion of a surface of the device or the component, respectively, the composition.

Abstract: A medicinal inhalation device having applied to a surface thereof a composition comprising a multifunctional polyfluoropolyether silane.

Abstract: A medicinal inhalation device having a non-metal coating coated on at least a portion thereof, and onto which non-metal coating an at least partially fluorinated compound is then covalently bonded.

Abstract: A medicinal inhalation device having a non-metal coating applied by plasma deposition under ion bombardment conditions.

Abstract: A metered dose valve for use in a pressurized metered dose dispenser for dispensing a metered dose of an aerosol formulation comprising particles of a medicament suspended in liquefied propellant, optionally in combination with one or more excipients, said valve comprising a metering chamber and at least one porous, fluid permeable, particulate semi-permeable body, said at least one porous body being positioned within a region of the interior conduit of the valve, for example within the metering chamber, or a pre-metering chamber and/or an internal channel upstream of the metering chamber.

Abstract: A pressurized metered dose dispenser (100) for dispensing an aerosol formulation comprising particles of a medicament suspended in liquefied propellant, optionally in combination with one or more excipients, the dispenser comprising an aerosol container (1) equipped with a metered dose valve (10), where a formulation chamber is defined in part by the internal walls of the container, and wherein the dispenser further comprises a porous, fluid permeable, particulate semi-permeable body (40) located within the formulation chamber adjacent to the metered dose valve.

Abstract: Use of particulate bulking agents having an extremely small mass median diameter of less than one micron, preferably less than 300 nm, in pharmaceutical aerosol formulations comprising a suspension of drug particles in a propellant. Examples of bulking agents include ascorbic acid, saccharides, polysaccharides, amino acids, organic and inorganic salts, urea, and propyliodone.

Abstract: A pharmaceutical aerosol formulation comprising particles of formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation; a compound of the formula (I), in which: R1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R2 is acetyl or isobutanoyl, said compound of formula (I) being dissolved in the formulation; and a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof.

Abstract: A pharmaceutical suspension aerosol formulation containing HFA-227 as a propellant.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: A method of making a medicinal inhalation device with a fluorocarbon (CF2)n-type polymer thin film coating by pyrolyzing a monomer gas to produce polymerizable CF2 species in the vicinity of the surface on which the fluorocarbon polymer film is to be formed, and maintaining the surface at a lower temperature than that of the heat source to induce deposition and polymerization of CF2 species on the surface.

Abstract: A metered dose aerosol valve that minimizes loss of prime and loss of drug dose by having a one-way valve mechanism positioned toward the end of a transfer passage that allows drug substance to pass from the aerosol container into the metering chamber, but not back.

Abstract: A metered dose aerosol valve that minimizes loss of prime and loss of drug dose by having a one-way valve mechanism positioned toward the end of a transfer passage that allows drug substance to pass from the aerosol container into the metering chamber, but not back.

Abstract: A pharmaceutical suspension formulation suitable for aerosol administration having from 0.0025 to 0.1% w/w of micronized Formoterol, or an acid addition salt thereof, from 0.1 to 5.0% w/w ethanol, HFA 134a, HFA 227 or a mixture of HFA 227 and HFA 134a, and optionally a surfactant other than a monoacetylated or diacetylated monoglyceride, the formulation being further characterized in that it exhibits substantially no growth in particle size or change in crystal morphology of the drug over a prolonged period, is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug.

Abstract: A pharmaceutical aerosol formulation, suitable for administration by oral or nasal inhalation, containing a suspension of particulate budesonide, hydrofluoroalkane propellant and, optionally, additional hydrofluoroalkane propellants, surfactant selected from oleic acid, sorbitan oleates and lecithin, and adjuvant have a Kauri-butanol value of at least 10.

Abstract: A metered dose dispensing valve having a movable agitator in the metering chamber and/or the pre-metering region of the valve.

Abstract: Metered dose dispensing valves providing good dosage reproducibility with formulations having a propensity to cream and with low concentration formulations. Valves having a tank retaining cup have a small inlet aperture of no more than 0.7 mm and preferably the tank retaining cup follows the configuration of the end of the valve stem. Valves having a bottle emptier attached to the valve stem have a filling channel in the valve stem which protrudes only slightly from the metering chamber when the valve is in its inoperative position.